The AMDS is an aortic arch remodeling device for use in the treatment of acute DeBakey Type I aortic dissections ... days attributed to comorbidities and dissection-related complications.

Artivion, Inc. , a leading cardiac and vascular surgery company focused on aortic disease, today announced data from the AMDS PERSEVERE clinical trial (the "IDE") was presented in a Late-Breaking ...

DeBakey Department of Surgery ... can be deployed over the abdominal visceral vessels in the setting of aortic dissection or malperfusion syndrome.

Oppenheimer reiterated its Outperform rating on Artivion Inc. (NYSE: AORT) shares, maintaining a $32.00 price target. The stock has shown remarkable momentum, delivering an 82% return over the past ...

PERSEVERE is a prospective, multicenter, nonrandomized clinical trial to determine if patients with acute DeBakey type I aortic dissection can be treated safely and effectively using the AMDS device.

Earlie Smith experienced an aortic dissection. Months later, her brother, Larry Smith, also had one. The same doctor helped ...

This is an emergency, Conner said. About 50% of people who have an aortic dissection die at home. Of the other 50% who make ...

The UK’s first aortic specialist nurse has been chosen to lead a new virtual consultation service for aortic dissection patients launched by a national charity. Emma Hope, who retired from the NHS ...

Full IDE Data Set Demonstrates Sustained Benefit at One Year with Use of AMDS in Acute DeBakey Type I (ADTI ... days attributed to comorbidities and dissection-related complications.